AQR Capital Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

AQR Capital Management’s Portfolio VIRX Stock Details VIRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-128	Closed	-$191K	–	2639
2014 Q3	$191K	Hold	128	–	–	﹤0.01%	2352
2014 Q2	$175K	Sell	128 -174	-58%	-$202K	﹤0.01%	2396
2014 Q1	$420K	Hold	302	–	–	﹤0.01%	2124
2013 Q4	$301K	Sell	302 -60	-17%	-$62K	﹤0.01%	2300
2013 Q3	$377K	Hold	362	–	–	﹤0.01%	2114
2013 Q2	$396K	Buy	+362	New	+$403K	﹤0.01%	1977

Other funds holding VIRX

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

VAM

Visium Asset Management New York $1.43B AUM 3.58% 1-Year Est. Return

First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return

AQR Capital Management's VIRX Position: Q4 2014 in Review

AQR Capital Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q4 2014, closing a stake of 128 shares — an estimated $191K sold.

AQR Capital Management first reported a position in VIRX in Q2 2013 and held it in 6 quarters. The position peaked at $420K in Q1 2014. 78 funds tracked by Wall St. Rank hold VIRX as of Q4 2014.

AQR Capital Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q4 2014 after selling out during the quarter.
AQR Capital Management sold 128 Viracta Therapeutics, Inc. Common Stock shares in Q4 2014, an estimated $191K.
AQR Capital Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2013 and held it in 6 quarters.
AQR Capital Management's Viracta Therapeutics, Inc. Common Stock position peaked at $420K in Q1 2014.
78 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q4 2014.

Based on AQR Capital Management's 13F filing for Q4 2014, filed 17 Feb 2015.